Pedro Cuevas Selected Research

Neomycin

12/2004	Perivascular delivery of neomycin inhibits the activation of NF-kappaB and MAPK pathways, and prevents neointimal hyperplasia and stenosis after arterial injury.
6/2004	Differentiation-inducing activity of neomycin in cultured rat glioma cells.
4/2004	Neomycin inhibits glioma cell migration.
10/2003	Antiproliferative action of neomycin is associated with inhibition of cyclin D1 activation in glioma cells.
4/2003	Glioma cell-associated sustained activation of the transcription factor, nuclear factor-kappa B, was inhibited by neomycin.
1/2003	Dual blockade of mitogen-activated protein kinases ERK-1 (p42) and ERK-2 (p44) and cyclic AMP response element binding protein (CREB) by neomycin inhibits glioma cell proliferation.
9/2002	Inhibition of rat glioma growth by neomycin. Preliminary report.
6/2002	Antiproliferative effect of neomycin in glioma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pedro Cuevas Research Topics

Disease

10	Neoplasms (Cancer) 12/2011 - 06/2002
9	Glioma (Gliomas) 02/2015 - 06/2002
9	Erectile Dysfunction 05/2014 - 01/2003
2	Carcinogenesis 02/2015 - 12/2011
2	Inflammation (Inflammations) 02/2015 - 12/2004
2	Glioblastoma (Glioblastoma Multiforme) 03/2011 - 10/2003
1	Contact Dermatitis (Eczema, Contact) 02/2015
1	Dermatitis 02/2015
1	Edema (Dropsy) 02/2015
1	Vitreous Hemorrhage 01/2015
1	Dry Eye Syndromes (Dry Eye Syndrome) 01/2015
1	Obesity 02/2013
1	Stargardt Disease 10/2012
1	Carcinoma (Carcinomatosis) 09/2012
1	Macular Degeneration (Age-Related Maculopathy) 09/2012
1	Pterygium 03/2012
1	Basal Cell Carcinoma (Rodent Ulcer) 12/2011
1	Rosacea (Acne Rosacea) 10/2011
1	Pathologic Processes 09/2011
1	Alkaptonuria 04/2010
1	Hypersensitivity (Allergy) 11/2006
1	Atrophy 09/2005
1	Psoriasis (Pustulosis Palmaris et Plantaris) 09/2005
1	Hyperplasia 12/2004
1	Pathologic Constriction (Stenosis) 12/2004
1	Wounds and Injuries (Trauma) 04/2004
1	Peripheral Nerve Injuries 03/2004
1	Hypoxia (Hypoxemia) 01/2003

Drug/Important Bio-Agent (IBA)

8	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 09/2012 - 06/2003
8	Neomycin FDA LinkGeneric 12/2004 - 06/2002
4	Proteins (Proteins, Gene)FDA Link 02/2015 - 01/2003
4	Phosphodiesterase 5 InhibitorsIBA 05/2014 - 12/2003
3	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 05/2014 - 05/2005
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2005 - 06/2002
2	Ophthalmic Solutions (Eye Drops)IBA 01/2015 - 03/2012
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2011 - 10/2005
2	endothelium-dependent hyperpolarization factor (EDHF)IBA 05/2005 - 06/2003
2	NF-kappa B (NF-kB)IBA 12/2004 - 04/2003
1	alpha,beta-diacryloxypropionic acid (DAPS)IBA 02/2015
1	ProstaglandinsIBA 02/2015
1	2,5-dihydroxyphenylsulfonateIBA 12/2011
1	potassium dobesilateIBA 10/2011
1	Doxycycline (Periostat)FDA LinkGeneric 10/2011
1	Metronidazole (Metric)FDA LinkGeneric 10/2011
1	azelaic acid (Azelex)FDA Link 10/2011
1	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 03/2011
1	Nebivolol FDA Link 08/2010
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 08/2010
1	2,5-dihydroxybenzoic acid (gentisic acid)IBA 04/2010
1	AntioxidantsIBA 02/2009
1	AC3056IBA 02/2009
1	Protein Kinase CIBA 11/2006
1	15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic AcidIBA 11/2006
1	bisindolylmaleimide IIBA 11/2006
1	Adrenal Cortex Hormones (Corticosteroids)IBA 09/2005
1	Glial Fibrillary Acidic ProteinIBA 06/2004
1	Therapeutic UsesIBA 10/2003
1	Cyclin D1IBA 10/2003
1	Transcription Factors (Transcription Factor)IBA 04/2003
1	Carrier Proteins (Binding Protein)IBA 01/2003
1	Arginine (L-Arginine)FDA Link 01/2003
1	ElementsIBA 01/2003
1	Cyclic AMP Response Element-Binding Protein (Cyclic AMP-Responsive DNA-Binding Protein)IBA 01/2003
1	Mitogen-Activated Protein KinasesIBA 01/2003
1	Cyclic AMP (AMP, Cyclic)IBA 01/2003
1	hydroxide ionIBA 01/2003

Therapy/Procedure

6	Therapeutics 10/2011 - 09/2002
2	Intravitreal Injections 01/2015 - 10/2012
2	Aftercare (After-Treatment) 01/2015 - 10/2012
1	Drug Therapy (Chemotherapy) 05/2014
1	Glycemic Control 02/2013
1	Gastric Bypass (Roux-en-Y Gastric Bypass) 02/2013
1	Combination Drug Therapy (Combination Chemotherapy) 03/2011